- Home
- FOXO vs ONCO Comparison
FOXO vs ONCO Comparison
Compare FOXO & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXO
- ONCO
- Stock Information
- Founded
- FOXO 2019
- ONCO 2018
- Country
- FOXO United States
- ONCO United States
- Employees
- FOXO N/A
- ONCO 12
- Industry
- FOXO Retail: Computer Software & Peripheral Equipment
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- FOXO Technology
- ONCO Health Care
- Exchange
- FOXO Nasdaq
- ONCO Nasdaq
- Market Cap
- FOXO 8.0M
- ONCO 9.4M
- IPO Year
- FOXO N/A
- ONCO 2022
- Fundamental
- Price
- FOXO $0.23
- ONCO $0.63
- Analyst Decision
- FOXO
- ONCO
- Analyst Count
- FOXO 0
- ONCO 0
- Target Price
- FOXO N/A
- ONCO N/A
- AVG Volume (30 Days)
- FOXO 13.5M
- ONCO 10.7M
- Earning Date
- FOXO 11-19-2024
- ONCO 12-10-2024
- Dividend Yield
- FOXO N/A
- ONCO N/A
- EPS Growth
- FOXO N/A
- ONCO N/A
- EPS
- FOXO N/A
- ONCO N/A
- Revenue
- FOXO $1,341,000.00
- ONCO $1,870,605.00
- Revenue This Year
- FOXO N/A
- ONCO N/A
- Revenue Next Year
- FOXO N/A
- ONCO N/A
- P/E Ratio
- FOXO N/A
- ONCO N/A
- Revenue Growth
- FOXO 196.03
- ONCO N/A
- 52 Week Low
- FOXO $0.13
- ONCO $0.32
- 52 Week High
- FOXO $1.30
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- FOXO 42.70
- ONCO 50.20
- Support Level
- FOXO $0.22
- ONCO $0.51
- Resistance Level
- FOXO $0.27
- ONCO $0.65
- Average True Range (ATR)
- FOXO 0.05
- ONCO 0.09
- MACD
- FOXO 0.00
- ONCO 0.03
- Stochastic Oscillator
- FOXO 23.53
- ONCO 31.87
About FOXO FOXO Technologies Inc.
FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. The company has two reportable business segments, FOXO Labs and FOXO Life.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.